Jonathan Whitfield
Child & Adolescent Psychiatry · Lake View Terrace, CANPI 1871622654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 24.8% of the total. 2025 is the largest year on record at $3,361, more than ten times the $69 reported in 2019. Among child & adolescent psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $28.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Supernus Pharmaceuticals, Inc.$830
- Otsuka America Pharmaceutical, Inc.$825
- Lundbeck LLC$810
- Takeda Pharmaceuticals U.S.A., Inc.$770
- plus $3K from 19 others
What the payments were for
- Food & beverage$10,378100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $2,572 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $1,596 |
| Supernus Pharmaceuticals, Inc. | 31 | $830 |
| Otsuka America Pharmaceutical, Inc. | 24 | $825 |
| Lundbeck LLC | 33 | $810 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $770 |
| Johnson & Johnson | 19 | $541 |
| Alkermes, Inc. | 15 | $354 |
| E.r. Squibb & Sons, L.L.C. | 5 | $325 |
| Ironshore Pharmaceuticals Inc. | 12 | $266 |
| Noven Therapeutics, LLC | 9 | $199 |
| Vanda Pharmaceuticals Inc. | 7 | $180 |
| Axsome Therapeutics, Inc. | 2 | $167 |
| Bausch Health US, LLC | 7 | $159 |
| Collegium Pharmaceutical, Inc. | 7 | $151 |
| Neurocrine Biosciences, Inc. | 6 | $132 |
| Corium, LLC | 5 | $130 |
| Teva Pharmaceuticals USA, Inc. | 4 | $112 |
| Tris Pharma Inc | 3 | $73 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Neos Therapeutics, LP | 2 | $40 |
| Almatica Pharma LLC | 1 | $31 |
| Noven Pharmaceuticals, Inc. | 1 | $28 |
| Adlon Therapeutics L.p. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,378 in reported general payments places this provider in the 95th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 22 | $16,072 |
| CelexaCitalopram Hydrobromide | 14 | $4,117 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $3,843 |
| Lisdexamfetamine Dimesylate | 16 | $2,584 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $1,643 |
| Aripiprazole | 12 | $1,010 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 21 | $638 |
| Doxepin Hcl | 34 | $608 |
| Bupropion XlBupropion Hcl | 29 | $436 |
| Lamotrigine | 29 | $334 |
| Paroxetine Hcl | 13 | $234 |
| Sertraline Hcl | 21 | $209 |
| Alprazolam | 40 | $184 |
| Lorazepam | 33 | $181 |
| Trazodone Hcl | 16 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $770 | $19,91533 claims |
| Almatica Pharma LLCSertraline Hcl | $31 | $20921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 child & adolescent psychiatry providers in California.
Other child & adolescent psychiatry in Lake View Terrace
- Kevin CoxOjai$2.9M
- Sukhjit BrarFresno$283K
- Manpreet SinghSacramento$104K
- Ihab SolimanCorona del Mar$93K
- Syed NaqviLos Angeles$69K
- Ellen HeynemanSan Diego$62K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
- Mohsin KhaliqueSan Ramon$20K
- Mansoor ZuberiWalnut Creek$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.